CONMED (CNMD) Expected to Announce Earnings on Wednesday

CONMED (NYSE:CNMD) is anticipated to announce its Q4 2025 results after the market closes on Wednesday, January 28th. Analysts expect the company to announce earnings of $1.32 per share and revenue of $366.8820 million for the quarter. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, January 28, 2026 at 4:30 PM ET.

CONMED (NYSE:CNMD) last issued its earnings results on Wednesday, November 5th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. CONMED had a net margin of 4.75% and a return on equity of 14.22%. The company had revenue of $337.93 million for the quarter, compared to analyst estimates of $334.76 million. During the same period in the prior year, the business posted $1.05 earnings per share. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Trading Down 1.3%

Shares of CONMED stock opened at $41.63 on Monday. The company has a 50-day moving average of $41.59 and a two-hundred day moving average of $46.72. CONMED has a 12-month low of $38.32 and a 12-month high of $74.70. The company has a current ratio of 2.10, a quick ratio of 0.95 and a debt-to-equity ratio of 0.85. The stock has a market cap of $1.29 billion, a PE ratio of 20.31, a price-to-earnings-growth ratio of 1.87 and a beta of 0.96.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNMD. Kelleher Financial Advisors purchased a new stake in shares of CONMED during the third quarter worth about $28,000. Quarry LP boosted its position in CONMED by 244.8% during the third quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after acquiring an additional 617 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in CONMED in the 3rd quarter worth approximately $211,000. iSAM Funds UK Ltd acquired a new position in CONMED in the 2nd quarter valued at $215,000. Finally, Tower Research Capital LLC TRC raised its holdings in CONMED by 107.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,248 shares of the company’s stock valued at $221,000 after acquiring an additional 2,205 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Bank of America dropped their price objective on CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a research note on Monday, December 8th. Zacks Research lowered CONMED from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. Piper Sandler dropped their price target on CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. JPMorgan Chase & Co. cut their price target on CONMED from $58.00 to $52.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of CONMED in a research note on Wednesday. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $53.67.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.